CAR-T treatment for blood cancers with certain markers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination CAR-T cell therapy for blood cancers that show specific markers (like CD19 or CD20) on tumor cells. It may help by using the patient’s immune cells to better find and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 months old.
- Your cancer cells have specific marker proteins (CD19, CD20, CD22, CD30, CD38, CD70, or CD123).
- You are generally healthy enough to do the treatment (KPS score over 80) and have expected survival of more than 1 month.
- Your blood counts are adequate, including hemoglobin above 80 g/L.
- You can safely undergo blood cell collection (no major problems that stop this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.